Summary: We investigated the influence of cyclosporine A on the concentration of tissue factor pathway inhibitor and von Willebrand factor antigen in plasma of heart transplant outpatients.
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The von Willebrand factor, also known as the multimeric macromolecular carrier of factor VIII coagulant activity, is secreted by endothelial cells and platelets. It serves as a connecting bridge between platelets and injury-exposed vascular subendothelium (10) (11) (12) . In laboratory diagnostics the von Willebrand factor serves as a marker of endothelial damage (13, 14) . The cellular von Willebrand factor is either secreted directly from the cytosol or after stimulation, when von Willebrand factor is released by von Weibel-Palade bodies.
We investigated the effect of cyclosporine A and/or polyethoxylated castor oil (cremophor EL) on the release of tissue factor pathway inhibitor from endothelial cells and used cell cultures to test this in vitro. Due to water insolubility, cyclosporine A is diluted in cremophor EL for intravenous injection and oral application with Sandimmune. We used cyclosporine A and cremophor EL at concentrations similar to in vivo levels during treatment of heart transplant patients.
Materials and Methods

Blood collection
In this study we included post heart transplant patients up to 6 years after transplantation immunosuppressed by cyclosporine A in therapeutical doses by oral administration. Blood samples were obtained from 50 blood donors and 50 heart transplant outpatients by drawing into citrated monovettes (9 vol blood to 1 vol 0.13 mol/1 trisodium citrate solution) or EDTA-prepared blood collection tubes. The blood collection of heart transplant patients was part of cyclosporine A monitoring every month. All samples were stored at -70 °C after centrifugation for 10 min at 2500 g until further use. After thawing, samples were centrifuged at 3000 g for 15 min to remove residual precipitates.
Measurement of tissue factor pathway inhibitor by a chromogenic substrate assay
The inhibitory activity of tissue factor pathway inhibitor was measured by a modified chromogenic substrate assay based on the ability to inhibit factor X activation by factor Vila/tissue factor complex. Tissue factor (25 μΐ) (dilution 1:80, Baxter, Unterschlei heim, Germany), 25 μΐ factor VII (0.0125 U, Sigma, Deisenhofen, Ger-!) Enzymes (clotting factors): Factor VII (EC 3.4.21.2) Factor X (EC 3.4.21.6) many) were added to 25 μΐ 0.075 mol/1 CaCl 2 and 25 μΐ factor X (0.025 U, Sigma, Deisenhofen, Germany) and incubated for 15 min at 37 °C under vigorous shaking. Samples (25 μΐ) (dilution up to 1:20) were added and after the same incubation conditions additional 25 μΐ factor X (0.4 U) were added, immediately. The chromogenic reaction was started after further incubation (10 min, 37 °C) by addition of 25 μΐ synthetic substrate (2.7 mmol/1 N-benzoyl-Ile-Glu-Gly-Arg-/7-nitroanilide, Chromogenix, Essen, Germany). The absorbance was measured at 405 nm after 30 min substrate incubation. The clotting factors and samples were diluted in assay buffer containing 0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl and 10 g/1 human albumin (Armour Pharma, Eschwege, Germany), pH 8.0.
Our test system was calibrated with recombinant truncated two domain tissue factor pathway inhibitor (domain 61 and 62) (Novo Nordisk, Gentofte, Denmark) diluted in assay buffer. The inhibitory activity of tissue factor pathway inhibitor in the substrate assay was suppressed by addition of 100 ng monospecific goat anti-tissue factor pathway inhibitor antibody (Novo Nordisk, Gentofte, Denmark) to the tested samples, thus indicating the specifity of the chromogenic test system.
Quantification of von Willebrand factor antigen
Von Willebrand factor antigen was measured in EDTA-plasma by a sandwich enzyme immunoassay (Boehringer Mannheim, Mannheim, Germany) and determined as percent of normal in plasma samples and mU/1 in cell culture supernatant.
Quantification of cyclosporine A
Cyclosporine A was determined in EDTA whole blood by an automated monoclonal antibody radio immunoassay not detecting cyclosporine metabolites (Ingstar/Sorin, D sseldorf, Germany).
Endothelial cell culture
Human umbilical vein endothelial cells (Promocell, Heidelberg, Germany) were incubated in serum-free growth medium containing human epidermal growth factor (10mg/l), bovine brain extract (12 mg/1), hydrocortisone (1 mg/1) and antibiotics (50 mg/1) (Promocell, Heidelberg, Germany). Human umbilical vein endothelial cells at the second passage after isolation were passaged in a solution of 0.5 g/1 trypsine and 0.2 g/1 EDTA (all Sigma, Deisenhofen, Germany) and seed in petri dishes of 60 mm diameter and grown to 80% confluence. The culture medium was refreshed before the cells were incubated with cyclosporine A (Sandimmun, Sandoz, Basle, Switzerland) in a concentration range from 20 to 200 mg/1 and/or cremophor EL (Sigma, Deisenhofen, Germany) from 1 to 50 mg/1.
Furthermore, endothelial cells were stimulated with calcium ionophore A 23187 (10~4mol/l) (Sigma, Deisenhofen, Germany) alone or in combination with cremophor EL (0-10 mg/1). Constitutive tissue factor pathway inhibitor release in unstimulated cells was tested in cell culture medium as described above (Promocell, Heidelberg, Germany).
Over a period of four days, tissue factor pathway inhibitor containing supernatants were removed from whole plate per day for quantification. The cell number of every plate was counted microscopically.
Homogeneity, morphology and differentiation of the cultured cells were determined by microscopical inspection and during cell growth by flow cytometry using a monoclonal antibody directed against E-selectin (ELAM-1, Biozol, Eching, Germany) as a specific endothelial surface marker and HLA-ABC monoclonal antibody (Dianova, Hamburg, Germany) in a Becton-Dickinson FACScan analyzer with CELLQuest software. Lactate dehydrogenase catalytic concentration was determined to exclude limited cell death and was measured with a Syncron CX7 clinical chemistry analyzer (Beckman, CA). We measured the proliferative activity of the cell cultures under the influence of stimulating agents by a Cell-Prolif-eration-Kit (Boehringer Mannheim, Mannheim, Germany). All buffers and reagents were negative for pyrogenes or endotoxins.
Statistical analysis
All statistical analyses between patient groups were performed by the Kolmogoroff-Smirnov-test and the median test to evaluate statistically significant differences between collectives. The Komolgoroff-Smirnov-test is most stringent for not normally distributed independent samples.
Values of p < 0.001 were considered to be statistically significant. For all groups and measurements we calculated the 90%-range, mean value and standard deviation.
Results
Measurement of cyclosporine A in plasma of heart transplant outpatients
The cyclosporine A concentration in stable heart transplant outpatients was determined in a range from 130-280 μ §/1 representing the application of therapeutical doses by oral application. This concentration of cyclosporine A was chosen as the basis for cell culture experiments, as well as cremophor EL in an equivalent dose.
Measurement of tissue factor pathway inhibitor in plasma samples
Tissue factor pathway inhibitor was quantified in plasma samples of 50 blood donors (25 of each sex from 18-60 years). The standard deviation and mean value were 10.3 μg/l and 32.4 μg/l, respectively. No significant sex or age dependencies were observed. Addition of 200 μg/l cyclosporine A to the plasma samples showed no effect on the tissue factor pathway inhibitor determination in the chromogenic substrate assay.
In contrast, the determination of tissue factor pathway inhibitor in 50 stable heart transplant immunosuppressed patients showed a 2-4 fold increased tissue factor pathway inhibitor concentration. The standard deviation and mean concentration were 28.8 μg/l and 98.2 μg/l, respectively ( fig. 1) . A correlation between cyclosporine A and tissue factor pathway inhibitor concentrations was not observed. The tissue factor pathway inhibitor concentrations determined with our test system were significantly lower than expected. However, a clear difference between normal individuals and heart transplant patients was shown.
Measurement of von Willebrand factor antigen in plasma samples
In heart transplant outpatients we also found considerably enhanced levels of von Willebrand factor antigen. The standard deviation and mean value of von Willebrand factor antigen in heart transplant patients were 90.7% and 185%, respectively. In blood donors the standard deviation was 29.9% and the mean value was 91% (fig. 2) . No sex or age dependencies were observed. A correlation between von Willebrand factor antigen and cyclosporine A concentration was not observed.
Endothelial cell culture
Flow cytometric analysis showed constant homogeneity of the cells stained with ELAM-1 and HLA-ABC monoclonal antibody during four days incubation. Lactate dehydrogenase concentration was constant in all tested samples over the four days (25-30 U/l).
The proliferative activity of the cell culture was constant during the incubation with cremophor EL ( fig. 3 ) for 14 h. A dose-dependent effect was not observed. Incubation with the ionophore A 23187 (10~4mol/l) alone or in combination with cremophor EL decreased the proliferative activity after Ih (fig. 4) . 
Blood donors
Heart transplant patients Fig. 1 Tissue factor pathway inhibitor concentration in titrated plasma of heart transplant patients (n = 50) compared to normal plasma from blood donors (n = 50) measured by a chromogenic substrate assay. The mean tissue factor pathway inhibitor concentration (bar) in organ transplant patients (90 μ §/1) is approximately 3-fold higher than in normal plasma (30 μg/l). The 90%-range in blood donors is 18-52 μg/l compared to 51 -153 μ^ in immunosuppressed patients. The mean concentration and 90% range of von Willebrand factor antigen were 91% and 53-146% in blood donors (n = 50) in contrast to 185% and 67-376% in heart transplant patients (n = 50). Cremophor EL (50 μg/l) alone did not alter the release of tissue factor pathway inhibitor compared to constitutive concentrations over a period of 24 hours. Increased tissue factor pathway inhibitor concentrations were observed after stimulation with the ionophore A 23187 (120-160 ng/10 5 cells). When cremophor EL and A 23187 were added in combination, an elevated tissue factor pathway inhibitor concentration was detected (190-265 ng/10 5 cells) ( fig. 6 ).
Measurement of von Willebrand factor antigen in endothelial cell culture supernatant
We also observed a significant correlation of von Willebrand factor antigen and cyclosporine A in cell culture medium dependent upon the cyclosporine concentration.
Von Willebrand factor antigen concentration did not alter significantly the first three days after cyclosporine A stimulation (3-9 mU/10 5 cells). A significant dose dependent effect of cyclosporine A was determined on day 4. 
Discussion
Tissue factor pathway inhibitor is the main natural plasma inhibitor of the extrinsic pathway of coagulation (15, 16) . Among other cell types tissue factor pathway inhibitor has been shown to be expressed by endothelial cells (17,18) , megakaryocytes, chondrocytes and synovial cells (19, 20) . The extrinsic pathway is initiated by the tissue factor/factor VII complex, which is inhibited by tissue factor pathway inhibitor. Thus it is involved in prolonging factor Xa mediated coagulation time.
In the present study we have investigated the tissue factor pathway inhibitor concentration in immunosuppressed heart transplant patients. In comparison to blood donors, the tissue factor pathway inhibitor concentration in transplant patients was significantly higher. The mean tissue factor pathway inhibitor concentration of the blood donors was 32 μ §/1, wherease the mean tissue factor pathway inhibitor concentration of immunosuppressed patients was 98 μg/l. Our chromogenic test system was calibrated with recombinant truncated tissue factor pathway inhibitor and was sufficient for the measurement of relative tissue factor pathway inhibitor concentration in transplant patients and normal individuals. However, the tissue factor pathway inhibitor concentrations determined with our chromogenic substrate assay were lower than published elsewhere (21, 22) . In contrast to other chromogenic assays we used recombinant tissue factor pathway inhibitor for calibration. The specific inhibitory activity of recombinant tissue factor pathway inhibitor is higher than in normal pooled plasma resulting in lower tissue factor pathway inhibitor values in the chromogenic substrate assay.
In immunosuppressed patients a 2-4 fold increase of the inhibitory activity of tissue factor pathway inhibitor was observed. The mean therapeutic cyclosporine A concentration was 200 μg/l. Cytotoxic effects of cyclosporine on endothelial cells are well known (1) . Therefore, the increase of tissue factor pathway inhibitor in plasma of heart transplant patients let us suggest that cyclosporine A influences the tissue factor pathway inhibitor release from the endothelium into the extracellular space. Thus the concentration of released free tissue factor pathway inhibitor (not bound to lipoproteins) may reflect the damage of the endothelium which is considered to be the origin of plasma tissue factor pathway inhibitor. This is confirmed because addition of cyclosporine A to plasma samples showed no tissue factor pathway inhibitor elevation. If cyclosporine A upregulated the synthesis of tissue factor pathway inhibitor, we would expect an increase of total tissue factor pathway inhibitor in plasma. The chromogenic assay system used in this study could not answer this question, because the increased concentration of only functional active tissue factor pathway inhibitor was determined.
As von Willebrand factor is also a marker of endothelial cell damage processes (23, 24) , we also measured plasma von Willebrand factor antigen in plasma of cardiac transplant patients. As with tissue factor pathway inhibitor, the von Willebrand factor antigen plasma levels were also increased in these individuals compared to healthy blood donors (tab. 1). From a pathophysiological point of view, the von Willebrand factor fosters platelet adhesion to damaged endothelium or exposed subendothelium. In persistently increased concentrations it may augment the cascade of events leading to transplant atherosclerosis. Newer investigations point to a role of von Willebrand factor as a coronary atherosclerosis risk (25) .
Our investigations with endothelial cell cultures demonstrated a dose-dependent effect of cyclosporine A on the cellular tissue factor pathway inhibitor and von Willebrand factor antigen release into the supernatant. Similar results were described with low molecular weight heparin on endothelial cells (26) . Since no cell differentiation or cell damage was determined by flow cytometry, by microscopic inspection and by the measurement of lactate dehydrogenase catalytic activity concentration in the cell culture medium, we conclude that no cytotoxic effects occurred during incubation with cyclosporine A in different concentrations. Therefore, we conclude that the release of tissue factor pathway inhibitor and von Willebrand factor antigen into the plasma of immunosuppressed patients is not a result of a severe vascular endothelial cell injury. The enhanced release can also be shown by coincubation with cremophor EL and nonphysiological agonist calcium ionophore A 23187. These results demonstrate that cremophor EL is the stimulating agent and cyclosporine A may function as cytosolic calcium modulator. Abraham and coworker (27) previously described the effect of cremophor EL in a rat model. In these experiments a reduction in kidney interlobular arterial blood flow, decreased cardiac output and induced hypotension were observed, thus indicating that cremophor EL becomes active when administered orally or intravenously. Furthermore, cyclosporine A is described to increase the Ca 2+ concentration in vascular smooth muscle cells (28) , hepatocytes (29) and mesangial cells (30) . Therefore, cyclosporine A seems to be responsible for the calcium influx to or release from intracellular stores.
Taken together, our results let us suggest that cyclosporine A and its vehicle cremophor EL stimulate endothelial cells in the same way and induce tissue factor pathway inhibitor release into the extracellular space. These findings are in accordance with the enhanced von Willebrand factor antigen release, as described earlier (1-3).
In contrast to von Willebrand factor, which has pro-haemostatic and atherogenic properties, tissue factor pathway inhibitor is a coagulation inhibitor and thus antithrombotic and probably anti-atherogenic.
The consequences of long term plasma elevation of tissue factor pathway inhibitor and von Willebrand factor antigen are difficult to calculate. Further studies on other endothelial-derived proteins in cyclosporine treated patients in connection with their coronary status are needed.
We recommend the measurement of endothelial derived proteins in clinical studies of new immunosuppressive agents (e. g. tacrolimus).
